- Professor of Medicine, University of Toronto
- Medical Director, Osteoporosis Centre, University of Toronto
- Consultant Endocrinologist
Dr. Josse graduated in Medicine with Honours from the University of London,UK. He holds Fellowships in Internal Medicine from the American College of Physicians, Royal College of Physicians of London and Internal Medicine and Endocrinology Fellowships from the Royal College of Physicians of Canada. He is also a fellow of the American College of Endocrinology.
Dr. Josse is a Full Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto, and a past Head of the Division of Endocrinology and Metabolism St. Michael’s Hospital. He is an Associate Scientist in the Li KaShing Knowledge Translation Institute, Director of the Metabolic Bone Disease and Osteoporosis Centre at St. Michael’s Hospital and Toronto Director of the Canadian Multicentre Osteoporosis Study (CaMos). He is a consultant to and a past Chair of the Scientific Advisory Council of Osteoporosis Canada. He is a member of the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) and a past President of the Canadian Society of Endocrinology and Metabolism (CSEM).
Dr. Josse has received multiple awards including the 2007 Distinction in Clinical Endocrinology Award from the American College of Endocrinology and the 2007 Robert Volpe Distinguished Service Award of the CSEM and recently the 2012 Queen Elizabeth II Diamond Jubilee Award Medal for significant achievement and remarkable service. He is also the recipient of the 2014 educator of the year award from CSEM.
His major clinical and research interests include osteoporosis, calcium metabolism, diabetes and various nutritional metabolic problems. He has co-authored over 260 articles in peer reviewed journals and lectures widely both nationally and internationally on various endocrine and metabolic topics.
“There will be an increased burden on health care resources as the population ages and chronic conditions such as osteoporosis and fracture will increase in prevalence. Closing the care gap and treating patients at risk for fragility fracture or those who have already had a fracture and are at risk for more is an important therapeutic goal. Identifying and treating this high risk population is a guideline recommendation and a current priority.”